{
  "candidates": [
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "bupivacaine",
      "ADJ": "FALSE",
      "count_nct": "2",
      "is_mab": "FALSE",
      "is_therapy": "TRUE",
      "nct_ids": "{'NCT04001101', 'NCT04006561', 'NCT04023669', 'NCT03992170', 'NCT03983759', 'NCT04015336', 'NCT04023292', 'NCT04019964', 'NCT03995147', 'NCT04004234', 'NCT04006522', 'NCT04025372', 'NCT04012619', 'NCT04001569', 'NCT03983811', 'NCT03977610', 'NCT04008706', 'NCT03994393', 'NCT04015778', 'NCT03998085', 'NCT04017819', 'NCT03996473', 'NCT03977571', 'NCT03989310', 'NCT04011059', 'NCT04020172', 'NCT04009109'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00000170 - Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia\n2. NCT00000451 - Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)\n3. NCT00000936 - A Study To Test An Anti-Rejection Therapy After Kidney Transplantation\n4. NCT00000948 - Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3\n5. NCT00001131 - Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients",
      "found_in_interventions": "5",
      "interventions": "NCT04001101: Anti-PD-1; RT and Anti-PD-1\nNCT04006561: A treatment protocol of combined chemoradiation delivered in the manner of hyperfractionated conformal whole-brain radiation therapy\nNCT04023669: Prexasertib; Cyclophosphamide; Gemcitabine; filgrastim; peg-filgrastim\nNCT03992170: Daratumumab\nNCT03983759: sintilimab maintenance\nNCT04015336: E7 TCR\nNCT04023292: Endocrine therapy; Endocrine therapy\nNCT04019964: Nivolumab\nNCT03995147: Pembrolizumab; R-CHOP Protocol\nNCT04004234: Manganese Chloride; nab-paclitaxel; Gemcitabine; anti-PD-1 antibody\nNCT04006522: 89Zr-DFO-Atezolizumab; Positron Emission Tomography/Computed Tomography\nNCT04025372: Bicalutamide; GnRH Agonist; Radiation Therapy; Darolutamide\nNCT04012619: Anlotinib Hydrochloride\nNCT04001569: AZD8186 in combination with paclitaxel\nNCT03983811: Icotinib; Placebo; chemotherapy\nNCT03977610: Ga-68 PSMA ligand\nNCT04008706: Acalabrutinib\nNCT03994393: Tremelimumab; Durvalumab\nNCT04015778: Nivolumab; carboplatin; nab-paclitaxel\nNCT03998085: Anlotinib Hydrochloride\nNCT04017819: 18F-C-SNAT4; Positron emission tomography (PET)/Computed tomography (CT) Scan\nNCT03996473: Radium-223 dichloride (Xofigo, BAY 88-8223); Pembrolizumab\nNCT03977571: Cytoreductive nephrectomy; Nivolumab; Ipilimumab; Tissue sampling\nNCT03989310: Manganese Chloride; nab-paclitaxel; Gemcitabine; anti-PD-1 antibody\nNCT04011059: Wharton's jelly-derived mesenchymal cells\nNCT04020172: Dobutamine\nNCT04009109: Lenalidomide; Ixazomib; Daratumumab Injection; Dexamethasone",
      "phases_from_nct": "{'Phase 1/Phase 2', 'N/A', 'Phase 1', None, 'Phase 3', 'Early Phase 1', 'Phase 2'}",
      "max_drug_phase": "Phase 4",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT03230851\"; \"NCT03230851\")",
      "canonical_name": "1: 3-Dimensional Conformal Radiation Therapy\n2: 3-Dimensional Ultrasound-Guided Radiation Therapy\n3: 4-Dimensional Conformal Radiation Therapy\n4: AVATAR\n5: Ablation Therapy",
      "brand_name": "1: 3D-CRT Conformal Therapy Radiation Conformal Therapy\n2: 3D Ultrasound-Guided Radiation Therapy\n3: 4D Conformal Radiation Therapy\n4: Audiovisual-Assisted Therapeutic Ambience in Radiation Therapy\n5: Ablation Local Ablation Therapy Local Ablative Therapy",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C16035\n2: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116429\n3: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116430\n4: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C164235\n5: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C20985",
      "fda_application": "\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "last_fda_dates": "Bupivacaine: Sep 04, 2020\nBupivacaine Hydrochloride: Sep 04, 2020\n\nMarcain: Sep 04, 2020\nMarcaine: Sep 04, 2020\nExparel: Feb 26, 2020",
      "fda_label_links": "\n\n\n\n\n\n\n\n\n\n\n\n\n"
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "therapy",
      "ADJ": "FALSE",
      "count_nct": "27",
      "is_mab": "FALSE",
      "is_therapy": "TRUE",
      "nct_ids": "{'NCT04001101', 'NCT04006561', 'NCT04023669', 'NCT03992170', 'NCT03983759', 'NCT04015336', 'NCT04023292', 'NCT04019964', 'NCT03995147', 'NCT04004234', 'NCT04006522', 'NCT04025372', 'NCT04012619', 'NCT04001569', 'NCT03983811', 'NCT03977610', 'NCT04008706', 'NCT03994393', 'NCT04015778', 'NCT03998085', 'NCT04017819', 'NCT03996473', 'NCT03977571', 'NCT03989310', 'NCT04011059', 'NCT04020172', 'NCT04009109'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00000170 - Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia\n2. NCT00000451 - Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)\n3. NCT00000936 - A Study To Test An Anti-Rejection Therapy After Kidney Transplantation\n4. NCT00000948 - Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3\n5. NCT00001131 - Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients",
      "found_in_interventions": "5",
      "interventions": "NCT04001101: Anti-PD-1; RT and Anti-PD-1\nNCT04006561: A treatment protocol of combined chemoradiation delivered in the manner of hyperfractionated conformal whole-brain radiation therapy\nNCT04023669: Prexasertib; Cyclophosphamide; Gemcitabine; filgrastim; peg-filgrastim\nNCT03992170: Daratumumab\nNCT03983759: sintilimab maintenance\nNCT04015336: E7 TCR\nNCT04023292: Endocrine therapy; Endocrine therapy\nNCT04019964: Nivolumab\nNCT03995147: Pembrolizumab; R-CHOP Protocol\nNCT04004234: Manganese Chloride; nab-paclitaxel; Gemcitabine; anti-PD-1 antibody\nNCT04006522: 89Zr-DFO-Atezolizumab; Positron Emission Tomography/Computed Tomography\nNCT04025372: Bicalutamide; GnRH Agonist; Radiation Therapy; Darolutamide\nNCT04012619: Anlotinib Hydrochloride\nNCT04001569: AZD8186 in combination with paclitaxel\nNCT03983811: Icotinib; Placebo; chemotherapy\nNCT03977610: Ga-68 PSMA ligand\nNCT04008706: Acalabrutinib\nNCT03994393: Tremelimumab; Durvalumab\nNCT04015778: Nivolumab; carboplatin; nab-paclitaxel\nNCT03998085: Anlotinib Hydrochloride\nNCT04017819: 18F-C-SNAT4; Positron emission tomography (PET)/Computed tomography (CT) Scan\nNCT03996473: Radium-223 dichloride (Xofigo, BAY 88-8223); Pembrolizumab\nNCT03977571: Cytoreductive nephrectomy; Nivolumab; Ipilimumab; Tissue sampling\nNCT03989310: Manganese Chloride; nab-paclitaxel; Gemcitabine; anti-PD-1 antibody\nNCT04011059: Wharton's jelly-derived mesenchymal cells\nNCT04020172: Dobutamine\nNCT04009109: Lenalidomide; Ixazomib; Daratumumab Injection; Dexamethasone",
      "phases_from_nct": "{'Phase 1/Phase 2', 'N/A', 'Phase 1', None, 'Phase 3', 'Early Phase 1', 'Phase 2'}",
      "max_drug_phase": "Phase 4",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT03230851\"; \"NCT03230851\")",
      "canonical_name": "1: 3-Dimensional Conformal Radiation Therapy\n2: 3-Dimensional Ultrasound-Guided Radiation Therapy\n3: 4-Dimensional Conformal Radiation Therapy\n4: AVATAR\n5: Ablation Therapy",
      "brand_name": "1: 3D-CRT Conformal Therapy Radiation Conformal Therapy\n2: 3D Ultrasound-Guided Radiation Therapy\n3: 4D Conformal Radiation Therapy\n4: Audiovisual-Assisted Therapeutic Ambience in Radiation Therapy\n5: Ablation Local Ablation Therapy Local Ablative Therapy",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C16035\n2: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116429\n3: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116430\n4: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C164235\n5: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C20985",
      "fda_application": "\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "last_fda_dates": "\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "fda_label_links": "\n\n\n\n\n\n\n\n\n\n\n\n\n"
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "radiation therapy",
      "ADJ": "FALSE",
      "count_nct": "16",
      "is_mab": "FALSE",
      "is_therapy": "TRUE",
      "nct_ids": "{'NCT03999710', 'NCT04001725', 'NCT04017377', 'NCT04001101', 'NCT04019262', 'NCT04021108', 'NCT03997643', 'NCT04015336', 'NCT03977311', 'NCT04025372', 'NCT04015661', 'NCT04013542', 'NCT03987087', 'NCT04022018', 'NCT04009044', 'NCT03975231'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00002484 - Radiation Therapy Using 3-Dimensional Treatment Planning in Patients With Non-small Cell Lung Cancer\n2. NCT00002537 - Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer\n3. NCT00002550 - Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer\n4. NCT00002551 - SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed\n5. NCT00002561 - Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease",
      "found_in_interventions": "0",
      "interventions": "NCT03999710: Radiation Therapy; Durvalumab\nNCT04001725: Dexamethasone; Metformin\nNCT04017377: Drug: Cisplatin; nab-paclitaxel\nNCT04001101: Anti-PD-1; RT and Anti-PD-1\nNCT04019262: Radiation Therapy; Temozolomide Oral Product\nNCT04021108: Nivolumab 240 MG\nNCT03997643: Radiotherapy to all dissected areas; Omit radiation to pN0 neck\nNCT04015336: E7 TCR\nNCT03977311: Sonalleve Magnetic Resonance-guided High Intensity Focused Ultrasound (MR-HIFU); Radiation therapy\nNCT04025372: Bicalutamide; GnRH Agonist; Radiation Therapy; Darolutamide\nNCT04015661: Nab-paclitaxel\nNCT04013542: Ipilimumab; Nivolumab; Radiation Therapy\nNCT03987087: Radiation; Chemotherapy\nNCT04022018: Adaptive radiotherapy; no adaptive radiotherapy\nNCT04009044: Afimoxifene; Core Biopsy; Questionnaire Administration\nNCT03975231: Dabrafenib; Intensity-Modulated Radiation Therapy; Trametinib",
      "phases_from_nct": "{'Phase 2', 'Phase 1', 'N/A', 'Phase 1/Phase 2'}",
      "max_drug_phase": "Phase 4",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT00686725\"; \"NCT00686725\")",
      "canonical_name": "1: 3-Dimensional Conformal Radiation Therapy\n2: 3-Dimensional Ultrasound-Guided Radiation Therapy\n3: 4-Dimensional Conformal Radiation Therapy\n4: AVATAR\n5: Accelerated Radiation Therapy",
      "brand_name": "1: 3D-CRT Conformal Therapy Radiation Conformal Therapy\n2: 3D Ultrasound-Guided Radiation Therapy\n3: 4D Conformal Radiation Therapy\n4: Audiovisual-Assisted Therapeutic Ambience in Radiation Therapy\n5: not found",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C16035\n2: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116429\n3: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116430\n4: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C164235\n5: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C94422",
      "fda_application": "\n\n\n\n\n\n\n\n\n\n",
      "last_fda_dates": "\n\n\n\n\n\n\n\n\n\n",
      "fda_label_links": "\n\n\n\n\n\n\n\n\n\n"
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "chemoradiotherapy",
      "ADJ": "FALSE",
      "count_nct": "13",
      "is_mab": "FALSE",
      "is_therapy": "TRUE",
      "nct_ids": "{'NCT03993249', 'NCT04009876', 'NCT04009265', 'NCT04006041', 'NCT03990532', 'NCT03984578', 'NCT04015661', 'NCT03985046', 'NCT04026412', 'NCT04005170', 'NCT03991104', 'NCT03997435', 'NCT03973008'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00004031 - SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma\n2. NCT00030771 - Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients\n3. NCT00059826 - Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer\n4. NCT00062439 - S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors\n5. NCT00069953 - Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction",
      "found_in_interventions": "2",
      "interventions": "NCT03993249: Nivolumab; chemoradiotherapy\nNCT04009876: nal-IRI; Surgical resection; Watch-and-wait; 5-FU/LV; Oxaliplatin\nNCT04009265: adjuvant treatment\nNCT04006041: Toripalimab; Paclitaxel/cisplatin; Intensity-modulated radiotherapy; Esophagectomy\nNCT03990532: treatment group(phase I); treatment group (phase II)\nNCT03984578: CAPEOX; Pembrolizumab; Capecitabine/ 5-FU; Pembrolizumab; Surgical resection\nNCT04015661: Nab-paclitaxel\nNCT03985046: Sintilimab plus Chemotherapy\nNCT04026412: nivolumab; ipilimumab; durvalumab\nNCT04005170: Toripalimab; Paclitaxel/Cisplatin; Intensity-modulated radiotherapy\nNCT03991104: Oxaliplatin; S-1 capsule; Intensity modulated radiotherapy (IMRT)\nNCT03997435: Control arm; Experimental arm\nNCT03973008: Adjuvant Chemoradiotherapy; Adjuvant Chemotherapy",
      "phases_from_nct": "{'Phase 1/Phase 2', 'Phase 1', 'N/A', 'Phase 3', 'Phase 2'}",
      "max_drug_phase": "Phase 4",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT04164797\"; \"NCT04164797\")",
      "canonical_name": "1: Chemoradiotherapy",
      "brand_name": "1: CRT CRTx Chemoradiation RCTx RT-CT Radiochemotherapy",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C94626",
      "fda_application": "\n\n\n\n\n\n",
      "last_fda_dates": "\n\n\n\n\n\n",
      "fda_label_links": "\n\n\n\n\n\n"
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "placebo",
      "ADJ": "FALSE",
      "count_nct": "12",
      "is_mab": "FALSE",
      "is_therapy": "FALSE",
      "nct_ids": "{'NCT03990974', 'NCT03976362', 'NCT04003142', 'NCT04003389', 'NCT04025879', 'NCT03988231', 'NCT03980054', 'NCT04003155', 'NCT04003636', 'NCT03975647', 'NCT03985046', 'NCT04005716'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00000817 - The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients\n2. NCT00000829 - A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants\n3. NCT00005922 - Conditioning, the Placebo Effect, and Psoriasis\n4. NCT00007605 - Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm\n5. NCT00029536 - Progesterone vs Placebo Therapy for Women With Epilepsy",
      "found_in_interventions": "9",
      "interventions": "NCT03990974: postoperative antimicrobial prophylaxis; No postoperative antimicrobial prophylaxis\nNCT03976362: Pembrolizumab; Carboplatin; Paclitaxel; Nab-paclitaxel; Olaparib; Placebo\nNCT04003142: fezolinetant; placebo\nNCT04003389: fezolinetant; placebo\nNCT04025879: Nivolumab; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed; Placebo; Docetaxel\nNCT03988231: Receipt of enoxaparin; Placebo\nNCT03980054: Pyrotinib; Placebo\nNCT04003155: fezolinetant; placebo\nNCT04003636: Pembrolizumab; Gemcitabine; Cisplatin; Placebo\nNCT03975647: tucatinib; placebo; T-DM1\nNCT03985046: Sintilimab plus Chemotherapy\nNCT04005716: Tislelizumab, Carboplatin /Cisplatin, Etoposide; Carboplatin / Cisplatin, Etoposide",
      "phases_from_nct": "{'Phase 1', 'Phase 3', 'Phase 4'}",
      "max_drug_phase": "Phase 4",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT02240680\"; \"NCT02240680\")",
      "canonical_name": "1: Placebo Administration",
      "brand_name": "1: not found",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116558",
      "fda_application": "",
      "last_fda_dates": "",
      "fda_label_links": ""
    },
    {
      "TP": "1",
      "Add_to_black_list": "",
      "candidate": "toripalimab",
      "ADJ": "FALSE",
      "count_nct": "7",
      "is_mab": "TRUE",
      "is_therapy": "FALSE",
      "nct_ids": "{'NCT03982680', 'NCT04010071', 'NCT04006041', 'NCT04005170', 'NCT04025931', 'NCT03992911', 'NCT04012606'}",
      "found_in_avicenna_therapy": "1: Toripalimab",
      "found_in_avicenna_count": "1",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT02836795 - Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors\n2. NCT02915432 - The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC\n3. NCT03086174 - Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma\n4. NCT03113266 - Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma\n5. NCT03316144 - Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma",
      "found_in_interventions": "7",
      "interventions": "NCT03982680: Toripalimab; Gemcitabine; 5- fluorine pyrimidine\nNCT04010071: axitinib plus toripalimab\nNCT04006041: Toripalimab; Paclitaxel/cisplatin; Intensity-modulated radiotherapy; Esophagectomy\nNCT04005170: Toripalimab; Paclitaxel/Cisplatin; Intensity-modulated radiotherapy\nNCT04025931: chidamide and toripalimab\nNCT03992911: Simmtecan, 5-FU and l-LV; Toripalimab; Etoposide, Cisplatin; Etoposide, Carboplatin\nNCT04012606: TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo",
      "phases_from_nct": "{'Phase 2', 'Phase 2/Phase 3', 'Phase 3'}",
      "max_drug_phase": "Phase 3",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT04453813\"; \"NCT04453813\")",
      "canonical_name": "1: Toripalimab",
      "brand_name": "1: not found",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C131334",
      "fda_application": "",
      "last_fda_dates": "",
      "fda_label_links": ""
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "platinum",
      "ADJ": "FALSE",
      "count_nct": "6",
      "is_mab": "FALSE",
      "is_therapy": "FALSE",
      "nct_ids": "{'NCT03976375', 'NCT04016389', 'NCT03992885', 'NCT03980925', 'NCT03976323', 'NCT04012606'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00059618 - PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer\n2. NCT00066768 - Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer\n3. NCT00081276 - 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer\n4. NCT00085384 - PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer\n5. NCT00090610 - Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer",
      "found_in_interventions": "0",
      "interventions": "NCT03976375: Pembrolizumab; Lenvatinib; Docetaxel\nNCT04016389: Cisplatin; Carboplatin; Paclitaxel; Trachelectomy\nNCT03992885: Icotinib\nNCT03980925: Nivolumab; Carboplatin; Etoposide\nNCT03976323: Pembrolizumab; Pemetrexed; Carboplatin; Cisplatin; Olaparib\nNCT04012606: TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo",
      "phases_from_nct": "{'Phase 2', 'N/A', 'Phase 3'}",
      "max_drug_phase": "Phase 4",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT00451906\"; \"NCT00451906\")",
      "canonical_name": "1: Platinum Compound\n2: Platinum Doublet",
      "brand_name": "1: Platinum Agents Platinum-Based Chemotherapy\n2: not found",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1450\n2: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C162261",
      "fda_application": "\n\n\n",
      "last_fda_dates": "\n\n\n",
      "fda_label_links": "\n\n\n"
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "monotherapy",
      "ADJ": "FALSE",
      "count_nct": "6",
      "is_mab": "FALSE",
      "is_therapy": "TRUE",
      "nct_ids": "{'NCT04024696', 'NCT04023071', 'NCT04025931', 'NCT04008030', 'NCT04004910', 'NCT04009681'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00064974 - Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes\n2. NCT00083616 - Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy\n3. NCT00085969 - Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus\n4. NCT00087516 - Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)\n5. NCT00089635 - Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer",
      "found_in_interventions": "0",
      "interventions": "NCT04024696: Abexinostat\nNCT04023071: FT516; Rituximab; Obinutuzumab; Cyclophosphamide; Fludarabine; IL-2\nNCT04025931: chidamide and toripalimab\nNCT04008030: Ipilimumab; Oxaliplatin; Leucovorin; Fluorouracil; Irinotecan; Bevacizumab; Cetuximab; Nivolumab\nNCT04004910: Plasma soluble TNF receptor pulldown; Plasma soluble TNF receptor pulldown + chemotherapy; Chemotherapy Drugs, Cancer\nNCT04009681: THOR-707; Checkpoint inhibitor; anti-EGFR antibody",
      "phases_from_nct": "{'Phase 1/Phase 2', 'Phase 1', 'Phase 2', 'Phase 3'}",
      "max_drug_phase": "Phase 4",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT04484259\"; \"NCT04484259\")",
      "canonical_name": "1: Genomically-Directed Monotherapy",
      "brand_name": "1: Genomically Directed Monotherapy",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C121155",
      "fda_application": "\n",
      "last_fda_dates": "\n",
      "fda_label_links": "\n"
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "combination therapy",
      "ADJ": "FALSE",
      "count_nct": "6",
      "is_mab": "FALSE",
      "is_therapy": "TRUE",
      "nct_ids": "{'NCT04001569', 'NCT03982173', 'NCT03994744', 'NCT03992885', 'NCT04025931', 'NCT04009681'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00001521 - Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia\n2. NCT00001964 - Combination Therapy of Severe Aplastic Anemia\n3. NCT00004001 - S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy\n4. NCT00005655 - Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer\n5. NCT00006047 - Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide",
      "found_in_interventions": "0",
      "interventions": "NCT04001569: AZD8186 in combination with paclitaxel\nNCT03982173: Tremelimumab; Durvalumab\nNCT03994744: PD-1 inhibitor; Metformin\nNCT03992885: Icotinib\nNCT04025931: chidamide and toripalimab\nNCT04009681: THOR-707; Checkpoint inhibitor; anti-EGFR antibody",
      "phases_from_nct": "{'Phase 2', 'Phase 1/Phase 2', 'Phase 3'}",
      "max_drug_phase": "Phase 4",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT03700801\"; \"NCT03700801\")",
      "canonical_name": "1: Multimodality Therapy",
      "brand_name": "1: Combination Therapy Combined Modality Therapy Combined Modality Treatment Combined Treatment Combined Treatment Modalities Multimodal Therapy Multimodal Treatment Multimodality Treatment",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C15212",
      "fda_application": "\n\n\n\n\n\n\n\n",
      "last_fda_dates": "\n\n\n\n\n\n\n\n",
      "fda_label_links": "\n\n\n\n\n\n\n\n"
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "pd",
      "ADJ": "FALSE",
      "count_nct": "5",
      "is_mab": "FALSE",
      "is_therapy": "FALSE",
      "nct_ids": "{'NCT04026841', 'NCT03993626', 'NCT04014101', 'NCT04015778', 'NCT04016116'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "0",
      "brief_titles(max_5)": "['Invalid_name']",
      "found_in_interventions": "1",
      "interventions": "NCT04026841: PD-1 antibody Sintilimab\nNCT03993626: CXD101 in Combination With Nivolumab\nNCT04014101: SHR-1210; apatinib\nNCT04015778: Nivolumab; carboplatin; nab-paclitaxel\nNCT04016116: Pembrolizumab; Ruxolitinib",
      "phases_from_nct": "{'Phase 1/Phase 2', 'Phase 2'}",
      "max_drug_phase": "Phase 4",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT03467425\"; \"NCT03467425\")",
      "canonical_name": "1: Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer Cells\n2: Anti-CSF1 Monoclonal Antibody PD-0360324\n3: Anti-LAG-3/PD-L1 Bispecific Antibody FS118\n4: Anti-PD-1 Fusion Protein AMP-224\n5: Anti-PD-1 Monoclonal Antibody AMG 404",
      "brand_name": "1: not found\n2: not found\n3: not found\n4: not found\n5: not found",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C174011\n2: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C131301\n3: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C150734\n4: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C97039\n5: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C161597",
      "fda_application": "\n\n\n\n",
      "last_fda_dates": "\n\n\n\n",
      "fda_label_links": "\n\n\n\n"
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "autologous",
      "ADJ": "TRUE",
      "count_nct": "5",
      "is_mab": "FALSE",
      "is_therapy": "FALSE",
      "nct_ids": "{'NCT04021992', 'NCT04015778', 'NCT03990493', 'NCT04011033', 'NCT04020575'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00001566 - A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas\n2. NCT00003425 - Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect\n3. NCT00005803 - Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma\n4. NCT00031564 - Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2\n5. NCT00043810 - Study of Gelonin Purging of Autologous Stem Cells for Transplantation",
      "found_in_interventions": "1",
      "interventions": "NCT04021992: gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab\nNCT04015778: Nivolumab; carboplatin; nab-paclitaxel\nNCT03990493: Dengue Virus-1 #45AZ5 (PV-001-DV); Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC)\nNCT04011033: iNKT cells; Cyclophosphamide; Human recombinated Interleukin-2; TACE\nNCT04020575: huMNC2-CAR44 CAR T cells; huMNC2-CAR44 CAR T cells @ RP2D",
      "phases_from_nct": "{'Phase 2', 'Phase 1', 'Phase 2/Phase 3'}",
      "max_drug_phase": "Phase 4",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT03110666\"; \"NCT03110666\")",
      "canonical_name": "1: 4H11-28z/fIL-12/EGFRt-expressing Autologous T-lymphocytes\n2: Acute Normovolemic Hemodilution\n3: Ad5-survivin-transduced Autologous Dendritic Cell Vaccine\n4: AdGMCAIX-transduced Autologous Dendritic Cells\n5: Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201",
      "brand_name": "1: not found\n2: Acute Isovolemic Hemodilution IAD Intraoperative Autologous Donation\n3: not found\n4: not found\n5: not found",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C123823\n2: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116547\n3: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C128860\n4: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C105809\n5: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C106242",
      "fda_application": "\n\n\n\n\n\nIAD: no num\n",
      "last_fda_dates": "\n\n\n\n\n\nIAD: Aug 10, 2020\n",
      "fda_label_links": "\n\n\n\n\n\n=HYPERLINK(\"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=b7ba12b8-32e2-4e83-a947-d0a1e91e65d1&type=pdf\";\"IAD\")\n"
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "inhibitors",
      "ADJ": "FALSE",
      "count_nct": "5",
      "is_mab": "FALSE",
      "is_therapy": "FALSE",
      "nct_ids": "{'NCT04025424', 'NCT03988114', 'NCT03983811', 'NCT04025931', 'NCT03982992'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00004578 - ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Na\u00efve HIV-Infected Subjects\n2. NCT00023231 - Pediatric Kidney Transplant Without Calcineurin Inhibitors\n3. NCT00038948 - Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients\n4. NCT00093847 - Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression\n5. NCT00094523 - Fosamprenavir Versus Other Protease Inhibitors",
      "found_in_interventions": "0",
      "interventions": "NCT04025424: Genetic tests of the available tumor and plasma samples\nNCT03988114: Abemaciclib; Nonsteroidal Aromatase Inhibitor (NSAI)\nNCT03983811: Icotinib; Placebo; chemotherapy\nNCT04025931: chidamide and toripalimab\nNCT03982992: Blinatumomab in combination with donor lymphocyte infusion",
      "phases_from_nct": "{'Phase 2', 'N/A', None, 'Phase 4'}",
      "max_drug_phase": "Phase 4",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT02092506\"; \"NCT02092506\")",
      "canonical_name": "1: Antimitotic Agent\n2: Dihydroorotate Dehydrogenase Inhibitor\n3: Dihydropyrimidine Dehydrogenase Inhibitor\n4: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor\n5: Farnesyl Transferase Inhibitor",
      "brand_name": "1: Antimitotic Drugs Antimitotics Microtubular Function Inhibitors Mitosis Inhibitor Agents Mitosis Inhibitor Drugs Mitosis Inhibitors Mitotic Inhibitor Agents Mitotic Inhibitor Drugs Mitotic Inhibitors\n2: Dihydroorotate Dehydrogenase Inhibitors\n3: DPD Inhibitors Dihydrothymin Dehydrogenase Inhibitors Dihydrouracil Dehydrogenase Inhibitors NADP Inhibitors\n4: EGFR Blocker EGFR Inhibitor EGFR Tyrosine Kinase Inhibitor EGFR Tyrosine Kinase Inhibitors EGFR-TK Inhibitor Epidermal Growth Factor Receptor Inhibitor Epidermal Growth-Factor Receptor Inhibitors\n5: Farnesyl Transferase Inhibitors Farnesyltransferase Inhibitors Protein Farnesyltransferase Inhibitor Protein Farnesyltransferase Inhibitors",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C273\n2: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2169\n3: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2019\n4: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2167\n5: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2020",
      "fda_application": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "last_fda_dates": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
      "fda_label_links": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n"
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "evaluate",
      "ADJ": "FALSE",
      "count_nct": "5",
      "is_mab": "FALSE",
      "is_therapy": "FALSE",
      "nct_ids": "{'NCT03989336', 'NCT04021082', 'NCT04003623', 'NCT03976882', 'NCT03991559'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00000774 - A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers\n2. NCT00004978 - An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy\n3. NCT00006154 - A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection\n4. NCT00022672 - A Study to Evaluate the Efficacy and Safety of Herceptin\u00ae (Trastuzumab) in Combination With Arimidex\u00ae (Anastrozole) an Aromatase Inhibitor Compared to Arimidex\u00ae Alone in Patients With Metastatic Breast Cancer\n5. NCT00035529 - A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis",
      "found_in_interventions": "0",
      "interventions": "NCT03989336: Manganese Chloride; nab-paclitaxel; Platinum chemotherapy; Sintilimab\nNCT04021082: Cerdulatinib\nNCT04003623: Pemigatinib\nNCT03976882: Hetrombopag; Placebo\nNCT03991559: Manganese Chloride; Anti-PD-1 antibody; Systemic therapy",
      "phases_from_nct": "{'Phase 1/Phase 2', 'Phase 1', 'Phase 2/Phase 3', 'Phase 3', 'Phase 2'}",
      "max_drug_phase": "Phase 4",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT01654809\"; \"NCT01654809\")",
      "canonical_name": "1: Evaluation",
      "brand_name": "1: Evaluate",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C25214",
      "fda_application": "\n",
      "last_fda_dates": "\n",
      "fda_label_links": "\n"
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "rp2d",
      "ADJ": "FALSE",
      "count_nct": "5",
      "is_mab": "FALSE",
      "is_therapy": "FALSE",
      "nct_ids": "{'NCT04006301', 'NCT04024696', 'NCT03989414', 'NCT04023669', 'NCT04017130'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "2",
      "brief_titles(max_5)": "1. NCT03821935 - Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors\n2. NCT04272203 - A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers",
      "found_in_interventions": "0",
      "interventions": "NCT04006301: JNJ-74699157\nNCT04024696: Abexinostat\nNCT03989414: CC-92480; Bortezomib; Dexamethasone; Daratumumab; Carfilzomib\nNCT04023669: Prexasertib; Cyclophosphamide; Gemcitabine; filgrastim; peg-filgrastim\nNCT04017130: TAK-169",
      "phases_from_nct": "{'Phase 1/Phase 2', 'Phase 1'}",
      "max_drug_phase": "Phase 1/Phase 2",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT02403193\"; \"NCT02403193\")",
      "canonical_name": "",
      "brand_name": "",
      "cancer_gov_link": "",
      "fda_application": "",
      "last_fda_dates": "",
      "fda_label_links": ""
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "pd-l1",
      "ADJ": "FALSE",
      "count_nct": "4",
      "is_mab": "FALSE",
      "is_therapy": "FALSE",
      "nct_ids": "{'NCT03996408', 'NCT03991559', 'NCT03991975', 'NCT04002622'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT01846416 - A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]\n2. NCT01984242 - A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin\u00ae) Compared to Sunitinib (Sutent\u00ae) in Participants With Untreated Advanced Renal Cell Carcinoma\n3. NCT02031458 - A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer\n4. NCT02041533 - An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)\n5. NCT02088112 - MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).",
      "found_in_interventions": "0",
      "interventions": "NCT03996408: Anlotinib; TQB2450\nNCT03991559: Manganese Chloride; Anti-PD-1 antibody; Systemic therapy\nNCT03991975: Anlotinib; TQB2450\nNCT04002622: TQB2450",
      "phases_from_nct": "{'Phase 1/Phase 2', 'Phase 1', 'Phase 2'}",
      "max_drug_phase": "Phase 3",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT02625623\"; \"NCT02625623\")",
      "canonical_name": "1: Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer Cells\n2: Anti-LAG-3/PD-L1 Bispecific Antibody FS118\n3: Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172\n4: Anti-PD-L1 Monoclonal Antibody\n5: Anti-PD-L1 Monoclonal Antibody FAZ053",
      "brand_name": "1: not found\n2: not found\n3: not found\n4: not found\n5: not found",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C174011\n2: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C150734\n3: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C160605\n4: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C128057\n5: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C131537",
      "fda_application": "\n\n\n\n",
      "last_fda_dates": "\n\n\n\n",
      "fda_label_links": "\n\n\n\n"
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "neoadjuvant treatment",
      "ADJ": "FALSE",
      "count_nct": "4",
      "is_mab": "FALSE",
      "is_therapy": "FALSE",
      "nct_ids": "{'NCT03994107', 'NCT04010552', 'NCT04017455', 'NCT03985891'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00128856 - Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients\n2. NCT00129376 - Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients\n3. NCT00153998 - Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)\n4. NCT00201773 - Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer\n5. NCT00254592 - Neoadjuvant Treatment of Breast Cancer",
      "found_in_interventions": "0",
      "interventions": "NCT03994107: Pegylated Liposomal Doxorubicin; Albumin-bound paclitaxel; Trastuzumab\nNCT04010552: NALRINOX combination\nNCT04017455: Atezolizumab; Bevacizumab\nNCT03985891: Anti-PD-1 Monoclonal Antibody JS001; Chemotherapy",
      "phases_from_nct": "{'Phase 1/Phase 2', 'Phase 2'}",
      "max_drug_phase": "Phase 3",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT03177382\"; \"NCT03177382\")",
      "canonical_name": "",
      "brand_name": "",
      "cancer_gov_link": "",
      "fda_application": "",
      "last_fda_dates": "",
      "fda_label_links": ""
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "standard",
      "ADJ": "TRUE",
      "count_nct": "4",
      "is_mab": "FALSE",
      "is_therapy": "FALSE",
      "nct_ids": "{'NCT04016116', 'NCT04006821', 'NCT04015336', 'NCT04025372'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00000817 - The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients\n2. NCT00002514 - Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission\n3. NCT00002784 - High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer\n4. NCT00003674 - Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer\n5. NCT00004412 - Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers",
      "found_in_interventions": "0",
      "interventions": "NCT04016116: Pembrolizumab; Ruxolitinib\nNCT04006821: PD-1 antibody; Apatinib mesylate\nNCT04015336: E7 TCR\nNCT04025372: Bicalutamide; GnRH Agonist; Radiation Therapy; Darolutamide",
      "phases_from_nct": "{'Phase 2'}",
      "max_drug_phase": "Phase 4",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT03907124\"; \"NCT03907124\")",
      "canonical_name": "1: Piperine Extract (Standardized)\n2: Standard Diet\n3: Standard Follow-Up Care\n4: Topical Fibrinogen-depleted Human Standardized Platelet Lysate CAM-101",
      "brand_name": "1: Bioperine Standardized Piperine Extract\n2: not found\n3: not found\n4: not found",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48417\n2: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C165169\n3: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116647\n4: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C154531",
      "fda_application": "\n\n\n\nBioperine: no num\n",
      "last_fda_dates": "\n\n\n\nBioperine: May 08, 2020\n",
      "fda_label_links": "\n\n\n\n=HYPERLINK(\"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=b9646777-4d61-4ee4-9bff-0077d52e90f8&type=pdf\";\"Bioperine\")\n"
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "stem cell transplantation",
      "ADJ": "FALSE",
      "count_nct": "4",
      "is_mab": "FALSE",
      "is_therapy": "FALSE",
      "nct_ids": "{'NCT04000698', 'NCT04021992', 'NCT04008888', 'NCT04002297'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00001880 - Stem Cell Transplantation for Metastatic Solid Tumors\n2. NCT00002514 - Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission\n3. NCT00002558 - Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors\n4. NCT00002594 - Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors\n5. NCT00002601 - Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma",
      "found_in_interventions": "0",
      "interventions": "NCT04000698: Preparative regimen\nNCT04021992: gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab\nNCT04008888: Allogeneic Hematopoietic Stem Cell Transplantation; Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2; Melphalan Given IV; Fludarabine Injection; PI and dexamethasone as maintenance therapy; PI+IMids+Dexamethasone as Consolidated Chemotherapy\nNCT04002297: zanubrutinib; bendamustine; rituximab",
      "phases_from_nct": "{'Phase 2', 'N/A', 'Phase 3'}",
      "max_drug_phase": "Phase 3",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT01246752\"; \"NCT01246752\")",
      "canonical_name": "1: Allogeneic Hematopoietic Stem Cell Transplantation\n2: Allogeneic Hematopoietic Stem Cell Transplantation with Donor Pretreatment\n3: Autologous Hematopoietic Stem Cell Transplantation\n4: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation\n5: Bone Marrow Stem Cell Transplantation",
      "brand_name": "1: Allogeneic Hematopoietic Cell Transplantation Allogeneic Stem Cell Transplantation HSC HSCT\n2: not found\n3: AHSCT Autologous Hematopoietic Cell Transplantation Autologous Stem Cell Transplantation\n4: auto-allo HCT\n5: BMSCT",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C46089\n2: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116462\n3: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C16039\n4: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116465\n5: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C25437",
      "fda_application": "\n\n\n\n\n\n\nHSC: no num\n\n\n\n\n\n",
      "last_fda_dates": "\n\n\n\n\n\n\nHSC: Jun 12, 2020\n\n\n\n\n\n",
      "fda_label_links": "\n\n\n\n\n\n\n=HYPERLINK(\"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=1e11f655-374c-59ac-e054-00144ff8d46c&type=pdf\";\"HSC\")\n\n\n\n\n\n"
    },
    {
      "TP": "",
      "Add_to_black_list": "1",
      "candidate": "allogeneic",
      "ADJ": "TRUE",
      "count_nct": "4",
      "is_mab": "FALSE",
      "is_therapy": "FALSE",
      "nct_ids": "{'NCT03977103', 'NCT03982992', 'NCT04000698', 'NCT04008888'}",
      "found_in_avicenna_therapy": "not found",
      "found_in_avicenna_count": "0",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT00004143 - Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes\n2. NCT00038818 - CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation\n3. NCT00038883 - Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies\n4. NCT00052598 - Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant\n5. NCT00053989 - NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders",
      "found_in_interventions": "1",
      "interventions": "NCT03977103: High dose irradiation conditioning + Treg/Tcon\nNCT03982992: Blinatumomab in combination with donor lymphocyte infusion\nNCT04000698: Preparative regimen\nNCT04008888: Allogeneic Hematopoietic Stem Cell Transplantation; Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2; Melphalan Given IV; Fludarabine Injection; PI and dexamethasone as maintenance therapy; PI+IMids+Dexamethasone as Consolidated Chemotherapy",
      "phases_from_nct": "{'Phase 2', 'N/A', 'Phase 3'}",
      "max_drug_phase": "Phase 3",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT00133224\"; \"NCT00133224\")",
      "canonical_name": "1: Adenovirus/Cytomegalovirus/Epstein-Barr Virus-specific Allogeneic Cytotoxic T Lymphocytes\n2: Alloantigen-specific Allogeneic Type 1 Regulatory T Cells T-allo10\n3: Allogeneic AML Antigen-expressing Dendritic Cell Vaccine\n4: Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes\n5: Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715",
      "brand_name": "1: not found\n2: not found\n3: DCOne\n4: not found\n5: not found",
      "cancer_gov_link": "1: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C100102\n2: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C134838\n3: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C97265\n4: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C101796\n5: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C165779",
      "fda_application": "\n\n\n\n\n",
      "last_fda_dates": "\n\n\n\n\n",
      "fda_label_links": "\n\n\n\n\n"
    },
    {
      "TP": "1",
      "Add_to_black_list": "0",
      "candidate": "tqb2450",
      "ADJ": "FALSE",
      "count_nct": "4",
      "is_mab": "FALSE",
      "is_therapy": "FALSE",
      "nct_ids": "{'NCT03996408', 'NCT03991975', 'NCT03983928', 'NCT04002622'}",
      "found_in_avicenna_therapy": "1: CBT-502",
      "found_in_avicenna_count": "1",
      "found_in_brief": "5",
      "brief_titles(max_5)": "1. NCT03460457 - Tolerance and Pharmacokinetics of TQB2450\n2. NCT03800706 - A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma\n3. NCT03825705 - A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma\n4. NCT03855358 - A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)\n5. NCT03855384 - Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck\uff08R/M SCCHN\uff09",
      "found_in_interventions": "4",
      "interventions": "NCT03996408: Anlotinib; TQB2450\nNCT03991975: Anlotinib; TQB2450\nNCT03983928: TQB2450; Anlotinib\nNCT04002622: TQB2450",
      "phases_from_nct": "{'Phase 1/Phase 2', 'Phase 2'}",
      "max_drug_phase": "Phase 3",
      "max_drug_nct": "=HYPERLINK(\"https://clinicaltrials.gov/ct2/show/NCT04405505\"; \"NCT04405505\")",
      "canonical_name": "",
      "brand_name": "",
      "cancer_gov_link": "",
      "fda_application": "",
      "last_fda_dates": "",
      "fda_label_links": ""
    }
  ]
}
